Vivimed Labs receives products approvals from Uzbekistan

Vivimed strategy is to increase its share of Branded products in CIS Markets.

Government allocates over Rs. 10,000 Cr in PLI scheme for bulk drugs and medical devices: Gowda

The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.

Approval accorded under PLI Scheme for domestic manufacturing of medical devices

The medical device Sector in India suffers from a considerable cost of manufacturing disability.

Shilpa Medicare CFO resigns

The commercial production in the SML was started in November 1989.

Aarti Drugs reports strong Q3 FY26 performance, PAT surges 58% YoY

On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY

Zydus receives FDA’s tentative approval for Dapagliflozin Tablets

Eli Lilly posts blockbuster Q4 2025 results, issues bullish 2026 outlook

US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices

AstraZeneca & Daiichi Sankyo gain priority review for Datroway in hard-to-treat breast cancer

The FDA’s regulatory decision is expected in Q2 2026 under the Prescription Drug User Fee Act (PDUFA)

FDA reviews AstraZeneca’s Saphnelo for subcutaneous use in Lupus

A final decision on the updated application is expected in the first half of 2026, while intravenous (IV) Saphnelo remains commercially available

Sanofi’s Venglustat shows breakthrough results in rare neurological Gaucher disease

Venglustat, a glucosylceramide synthase inhibitor (GCSi), works by reducing the abnormal buildup of sugar-and-fat molecules in cells and organs